Physician profile
Katherine Devillier
NPI 1164283909
$1,541.30
in general payments reported to CMS, 2019-2025
18 companies · $773 in 2025
The $773 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $769 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $356.98 | 2024-2025 | |
| Corium, LLC | $163.12 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.93 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $131.73 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $99.60 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $93.27 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $78.54 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $75.50 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $73.17 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $56.45 | 2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $47.94 | 2024-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Noven Therapeutics, LLC | $46.26 | 2024-2025 | Xelstrym |
| Neurocrine Biosciences, INC. | $37.99 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $36.34 | 2024-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $33.42 | 2024 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $25.79 | 2024 | Qelbree |
| Neos Therapeutics, Lp | $22.73 | 2025 | Exxua |
| Ironshore Pharmaceuticals INC. | $22.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Devillier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.